ciltacabtagene autoleucel
AXP000018.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- TNFRSF17
- Originator
- Legend Biotech
- Sponsor
- Janssen (Johnson & Johnson); Legend Biotech
Names
| Name | Type | Source |
|---|---|---|
| ciltacabtagene autoleucel | preferred name, INN | curator, ncit |
| Carvykti | brand | ncit |
| JNJ-4528 | code | press |
| JNJ-68284528 | code | ncit |
| LCAR-B38M | code | ncit |
| cilta-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- replication-incompetent lentiviral vector; the CAR carries two single-domain antibodies, giving two BCMA-binding domains, with 4-1BB costimulatory and CD3 zeta signalling domains
- Transgenes
- anti-BCMA chimeric antigen receptor (bivalent)
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C148498
- Wikidata
- Q111948874
- FDA UNII
- 0L1F17908Q
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2022-02-28 | approved | Carvykti | Adults with relapsed or refractory multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, and refractory to lenalidomide | source |
| EMA | EU | 2022-05-25 | approved | Carvykti | Adults with relapsed and refractory multiple myeloma after at least one prior therapy including an immunomodulatory agent and a proteasome inhibitor, who progressed on the last therapy and are refractory to lenalidomide | source |
| PMDA | JP | 2022-09-26 | approved | Carvykti | Relapsed or refractory multiple myeloma in patients with no prior BCMA-directed CAR T-cell therapy who have had at least three prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and who did not respond to or relapsed after the last of them | source |
Clinical trials (22)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Recruiting | Phase 1 | 2026-11 | 2028-08-01 | 32 | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM) |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | Recruiting | Phase 1 | 2025-12-02 | 2027-07-01 | 31 | Refractory Multiple Myeloma; Relapse Multiple Myeloma |
| NCT07149857 | A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Recruiting | Phase 2 | 2025-10-03 | 2028-04-12 | 60 | Multiple Myeloma |
| NCT06940297 | Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | Phase 2 | 2025-09-18 | 2031-08-15 | 44 | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study | Recruiting | 2025-01-15 | 2029-01 | 400 | AL Amyloidosis; Myeloma Multiple; Plasma Cell Leukemia | |
| NCT06623630 | Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | Recruiting | Phase 1 | 2024-12-04 | 2027-06-30 | 16 | Multiple Myeloma |
| NCT06574126 | Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma | Recruiting | Phase 2 | 2024-09-30 | 2032-09-30 | 20 | High Risk Smoldering Multiple Myeloma |
| NCT06550895 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | Active not recruiting | Phase 2 | 2024-09-16 | 2027-08-26 | 11 | Multiple Myeloma |
| NCT06577025 | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | Active not recruiting | Phase 2 | 2024-08-20 | 2030-09-02 | 43 | Multiple Myeloma |
| NCT05666700 | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study | Active not recruiting | Phase 1 | 2023-12-08 | 2027-01 | 10 | Extramedullary Myeloma |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | Active not recruiting | Phase 3 | 2023-10-10 | 2033-06 | 759 | Multiple Myeloma |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | Active not recruiting | Phase 2 | 2023-04-19 | 2025-12-15 | 20 | Multiple Myeloma; Smoldering Multiple Myeloma |
| NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | Completed | Phase 2 | 2022-05-13 | 2023-11-30 | 86 | Multiple Myeloma |
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Recruiting | Phase 4 | 2022-03-09 | 2037-07-29 | 295 | Multiple Myeloma |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | Active not recruiting | Phase 3 | 2021-08-19 | 2029-02-14 | 743 | Multiple Myeloma |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma | Active not recruiting | Phase 3 | 2020-06-12 | 2024-05-01 | 419 | Multiple Myeloma |
| NCT04133636 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | Active not recruiting | Phase 2 | 2019-11-07 | 2027-02-26 | 208 | Multiple Myeloma |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | Terminated | Phase 2 | 2019-01-23 | 2025-07-10 | 123 | Multiple Myeloma |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Completed | Phase 1/2 | 2018-06-29 | 2022-08-23 | 126 | Multiple Myeloma |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | Unknown | Phase 1/2 | 2015-10-02 | 2023-12-31 | 100 | Refractory or Relapsed Multiple Myeloma |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | Available | Multiple Myeloma | ||||
| NCT04452994 | Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | No longer available | Multiple Myeloma |
Unconfirmed matches (2)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07200089 | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | Recruiting | Phase 1 | 2026-06-05 | 2028-03-10 | 52 | Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma, Refractory | name in title: cilta-cel |
| NCT06947083 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | Recruiting | Phase 2 | 2025-05-27 | 2029-04 | 39 | Myeloma | name in title: cilta-cel |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40637727 | Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. | Haematologica | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41139561 | Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial. | Clinical lymphoma, myeloma & leukemia | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41257522 | Treatment-Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T-Cell Therapy. | Movement disorders clinical practice | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41519141 | Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. | The Lancet. Oncology | 2026 | cited by trial NCT04181827 |
| PMID 41592291 | Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. | Blood | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41627370 | Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. | Advances in therapy | 2026 | cited by trial NCT03548207 |
| PMID 41824255 | Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. | Journal of patient-reported outcomes | 2026 | cited by trial NCT04181827 |
| PMID 41853755 | Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report. | Leukemia research reports | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41886677 | Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy. | Blood cancer discovery | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41914448 | Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis. | American journal of hematology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41980929 | Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. | Blood cancer journal | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42004656 | Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. | Kidney medicine | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42004964 | Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report. | Frontiers in immunology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42010117 | Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. | Nature medicine | 2026 | cited by trial NCT05767359 |
| PMID 42084945 | Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. | JCI insight | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42253352 | Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel. | Blood cell therapy | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42284467 | Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. | Blood cancer discovery | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42351384 | Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma. | American journal of hematology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42370651 | Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy. | Journal of comparative effectiveness research | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42379467 | Kidney Transplantation Post-Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42392508 | Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42444648 | Steroid-resistant bilateral facial nerve palsies, ophthalmoparesis, and multilevel thoracic radiculopathy as immune effector cell-associated late-onset neurotoxicity after cilta-cel CAR-T therapy: a case report and review of similar cases. | Frontiers in neurology | 2026 | name in title: cilta-cel |
| PMID 42645380 | Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42747560 | Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. | Annals of hematology | 2026 | name in title: cilta-cel |
| PMID 42777241 | Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. | The New England journal of medicine | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42780369 | Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus. | Cureus | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42860893 | Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma. | Future oncology (London, England) | 2026 | cited by trial NCT03548207 |
| PMID 42871407 | Markedly Delayed Onset ICANS in the Setting of CAR T-Cell-Mediated Aseptic Meningoencephalitis: Two Cases. | The Neurohospitalist | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 39365257 | Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. | Blood | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 39756844 | Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. | The Lancet. Haematology | 2025 | cited by trial NCT04181827 |
| PMID 39938094 | CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. | The New England journal of medicine | 2025 | cited by trial NCT04181827 |
| PMID 39965175 | Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 39984633 | Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. | Nature medicine | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 40163799 | Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. | Blood | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40178605 | Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma. | Annals of hematology | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 40354013 | Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison. | Advances in therapy | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40459151 | Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | cited by trial NCT03548207 |
| PMID 40501515 | Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma. | Journal of hematology | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40613875 | Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting. | Advances in therapy | 2025 | cited by trial NCT04181827 |
| PMID 40738883 | Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement. | Blood cancer journal | 2025 | name in abstract: cilta-cel |
| PMID 40749169 | Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. | Blood | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 40768190 | Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma. | Advances in therapy | 2025 | cited by trial NCT04181827 |
| PMID 40875887 | Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. | Blood advances | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 41115887 | Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy. | Blood cancer journal | 2025 | name in title: cilta-cel |
| PMID 41342049 | Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series. | Kidney medicine | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 38369805 | Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. | British journal of haematology | 2024 | name in abstract: LCAR-B38M |
| PMID 38659046 | Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. | Journal of hematology & oncology | 2024 | cited by trial NCT03090659 |
| PMID 38697457 | Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. | Clinica chimica acta; international journal of clinical chemistry | 2024 | name in abstract: Carvykti |
| PMID 38713595 | FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | name in title: ciltacabtagene autoleucel |
| PMID 38776397 | Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. | Blood advances | 2024 | name in abstract: ciltacabtagene autoleucel |
| PMID 38865661 | Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. | The New England journal of medicine | 2024 | name in title: cilta-cel |
| PMID 39100867 | Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases. | Kidney medicine | 2024 | name in abstract: ciltacabtagene autoleucel |
| PMID 39110421 | Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. | Future oncology (London, England) | 2024 | cited by trial NCT04181827 |
| PMID 39162049 | Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. | Journal of comparative effectiveness research | 2024 | name in title: Carvykti |
| PMID 39234256 | Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. | Frontiers in immunology | 2024 | cited by trial NCT04181827 |
| PMID 39372422 | Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen. | Frontiers in immunology | 2024 | name in title: ciltacabtagene autoleucel |
| PMID 39507461 | How we manage multiple myeloma with clonal hematopoiesis of indeterminate potential (CHIP): a case report. | Annals of translational medicine | 2024 | name in abstract: ciltacabtagene autoleucel |
| PMID 35658469 | Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT03548207 |
| PMID 36095849 | Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. | Blood | 2023 | cited by trial NCT04133636 |
| PMID 36269898 | Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT03758417 |
| PMID 36357295 | Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. | Clinical lymphoma, myeloma & leukemia | 2023 | cited by trial NCT03548207 |
| PMID 36546453 | Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. | Haematologica | 2023 | cited by trial NCT03548207 |
| PMID 37137553 | BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. | Journal for immunotherapy of cancer | 2023 | cited by trial NCT03548207 |
| PMID 37270762 | Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. | Oncology and therapy | 2023 | cited by trial NCT03090659 |
| PMID 37272512 | Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. | The New England journal of medicine | 2023 | cited by trial NCT04181827 |
| PMID 37999117 | Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. | Current oncology (Toronto, Ont.) | 2023 | name in abstract: cilta-cel |
| PMID 34822128 | Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | Clinical drug investigation | 2022 | name in title: ciltacabtagene autoleucel |
| PMID 35764490 | Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. | Clinical lymphoma, myeloma & leukemia | 2022 | name in title: ciltacabtagene autoleucel |
| PMID 35794616 | Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). | Journal of hematology & oncology | 2022 | cited by trial NCT03090659 |
| PMID 36052883 | Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. | Cancer science | 2022 | name in title: ciltacabtagene autoleucel |
| PMID 36204820 | Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma. | Clinical and translational science | 2022 | cited by trial NCT03548207 |
| PMID 36215989 | Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. | The Lancet. Haematology | 2022 | cited by trial NCT03548207 |
| PMID 36496425 | Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report. | Journal of medical case reports | 2022 | name in title: LCAR-B38M |
| PMID 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet (London, England) | 2021 | cited by trial NCT03548207 |
| PMID 34256668 | Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. | Current medical research and opinion | 2021 | name in title: ciltacabtagene autoleucel |
| PMID 34893771 | Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. | Nature medicine | 2021 | cited by trial NCT03548207 |
| PMID 30988175 | Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. | Proceedings of the National Academy of Sciences of the United States of America | 2019 | name in abstract: LCAR-B38M |
| PMID 30572922 | A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. | Journal of hematology & oncology | 2018 | cited by trial NCT03090659 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 40994343 | Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches. | Haematologica | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41191534 | Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. | Blood advances | 2026 | name in title: cilta-cel |
| PMID 41349540 | A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. | Cancer cell | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41396414 | Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma. | International journal of hematology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2026 | name in abstract: cilta-cel |
| PMID 41448297 | Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis. | Critical reviews in oncology/hematology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41455802 | Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience. | Bone marrow transplantation | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41455805 | CAR T-cells in multiple myeloma: the race to the start line. | Bone marrow transplantation | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41485660 | Bridging discovery and therapy in precision medicine-Phage display as a catalyst for nanobody innovation: A review. | International journal of biological macromolecules | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41540109 | CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. | Nature medicine | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41547065 | Intra-procedure white blood cell monitoring as a predictor of collection efficiency in mononuclear cell apheresis. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2026 | name in abstract: Carvykti |
| PMID 41563628 | Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status? | Targeted oncology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41610427 | Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. | Blood | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41616604 | Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel. | Journal of the neurological sciences | 2026 | name in title: cilta-cel |
| PMID 41687609 | The cellular orchestra of CAR T success. | Cancer cell | 2026 | name in abstract: cilta-cel |
| PMID 41703026 | MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel. | Leukemia | 2026 | name in title: cilta-cel |
| PMID 41720163 | Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates. | Transplantation and cellular therapy | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41721717 | Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma. | Hematological oncology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41734332 | Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. | Expert review of pharmacoeconomics & outcomes research | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41744844 | BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41827691 | Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes. | Cancers | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41848013 | Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings. | Journal of medical economics | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41870621 | Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database. | Annals of hematology | 2026 | name in abstract: cilta-cel |
| PMID 41874852 | FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA. | Advances in therapy | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41886632 | Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma. | Blood advances | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41894686 | Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma. | Blood advances | 2026 | name in title: cilta-cel |
| PMID 41899614 | Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients. | Cancers | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41935039 | Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. | Blood cancer journal | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 41951449 | Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. | Clinical therapeutics | 2026 | name in abstract: cilta-cel |
| PMID 41961998 | Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. | Blood advances | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 41963287 | Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database. | Blood cancer journal | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42000954 | Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases. | Oncology and therapy | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42057607 | Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms. | Current medical research and opinion | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42086512 | Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. | American journal of hematology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42115674 | Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. | Bone marrow transplantation | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42144192 | Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42161729 | Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies. | Clinical lymphoma, myeloma & leukemia | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42163304 | Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis. | Journal of hematology & oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42163771 | [18F]Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. | Haematologica | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42169674 | Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma. | Leukemia & lymphoma | 2026 | name in title: cilta-cel |
| PMID 42227005 | Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma. | Clinical epidemiology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42252797 | Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma. | British journal of haematology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42260185 | Does ciltacabtagene autoleucel have a future in multiple myeloma? | Nature reviews. Clinical oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42345308 | A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma. | Current medical research and opinion | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42361980 | Real-World Safety, Efficacy, and Immune Recovery Following Out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma. | Transplantation and cellular therapy | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42365547 | IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment. | Oncology and therapy | 2026 | name in title: cilta-cel |
| PMID 42388416 | Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany. | HemaSphere | 2026 | name in title: cilta-cel |
| PMID 42418682 | Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma. | Blood | 2026 | name in title: cilta-cel |
| PMID 42449019 | Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma. | Nature reviews. Clinical oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42449020 | The future of ciltacabtagene autoleucel in multiple myeloma has just begun. | Nature reviews. Clinical oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42449578 | Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. | Cancers | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42471153 | Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42512374 | Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis. | Cancers | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42518303 | Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort. | Leukemia & lymphoma | 2026 | name in abstract: cilta-cel |
| PMID 42518817 | Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center. | Frontiers in oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42525783 | Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. | Science translational medicine | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42642985 | Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. | Current medical research and opinion | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42644320 | Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. | British journal of haematology | 2026 | name in title: cilta-cel |
| PMID 42660229 | Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience. | Transplantation and cellular therapy | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42675051 | Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. | Blood cancer journal | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42705499 | Delayed Neurologic and Enterocolitis Reporting Patterns for Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in EudraVigilance. | Transplantation and cellular therapy | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42724501 | Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143. | Translational cancer research | 2026 | name in title: cilta-cel |
| PMID 42727844 | Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2026 | name in title: cilta-cel |
| PMID 42728267 | Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity. | Blood cancer journal | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42759984 | Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products. | Journal for immunotherapy of cancer | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42778764 | Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy. | Nature medicine | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42779338 | Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. | Cancer | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42841179 | BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management. | European journal of haematology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42844619 | T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. | Journal of hematology & oncology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42844744 | Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42868529 | Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. | JMIR cancer | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42879175 | Cilta-cel CAR T-cell expansion and neurotoxicity. | Blood | 2026 | name in title: cilta-cel |
| PMID 42889616 | Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma. | Frontiers in oncology | 2026 | name in abstract: ciltacabtagene autoleucel |
| PMID 42901918 | The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program. | Nature communications | 2026 | name in title: cilta-cel |
| PMID 42908664 | Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database. | Frontiers in pharmacology | 2026 | name in abstract: Carvykti |
| PMID 42988507 | The Bottom Line: OOS Cilta-cel in MM. | Transplantation and cellular therapy | 2026 | name in title: cilta-cel |
| PMID 42991680 | Orthopnea From Phrenic Nerve Palsy After Ciltacabtagene Autoleucel CAR T-Cell Therapy in a Patient With Multiple Myeloma. | Journal of the advanced practitioner in oncology | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 42992382 | Correction to "Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis". | Cancer | 2026 | name in title: ciltacabtagene autoleucel |
| PMID 38718775 | Toxicity of CAR T-Cell Therapy for Multiple Myeloma. | Acta haematologica | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39373355 | B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice. | The Annals of pharmacotherapy | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39672542 | Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. | Transplantation and cellular therapy | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39729503 | BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. | Blood advances | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39748220 | Update on B-cell maturation antigen-directed therapies in AL amyloidosis. | British journal of haematology | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39779930 | T cell malignancies after CAR T cell therapy in the DESCAR-T registry. | Nature medicine | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 39822585 | Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. | HemaSphere | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 39915676 | International approvals of cilta-cel: a lens on CAR T cell regulation. | Nature reviews. Clinical oncology | 2025 | name in title: cilta-cel |
| PMID 39990276 | Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. | Cancer management and research | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40053892 | Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40095642 | Current Treatment Strategies for Multiple Myeloma at First Relapse. | Journal of clinical medicine | 2025 | name in abstract: cilta-cel |
| PMID 40098471 | Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable. | Future oncology (London, England) | 2025 | name in title: cilta-cel |
| PMID 40225701 | Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | ClinicoEconomics and outcomes research : CEOR | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 40246942 | CAR-T for multiple myeloma: practice pearls. | Bone marrow transplantation | 2025 | name in abstract: ciltacabtagene autoleucel |
| PMID 40295321 | The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy. | Discover oncology | 2025 | name in title: LCAR-B38M |
| PMID 40334078 | Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. | Blood advances | 2025 | name in title: ciltacabtagene autoleucel |
| PMID 40346502 | Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. | BMC cancer | 2025 | name in abstract: cilta-cel |
| PMID 40474425 | An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy. | Cell transplantation | 2025 | name in abstract: LCAR-B38M |
| PMID 40501407 | Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study. | Haematologica | 2025 | name in title: cilta-cel |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA316736 | Mechanisms of BCMA CAR-T-mediated enteritis in multiple myeloma patients | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | OH, DAVID YOONSUK | 2026–2026 | name in abstract: cilta-cel |
Notes
Bi-epitopic anti-BCMA VHH CAR. LCAR-B38M (Legend, China) and JNJ-68284528 treated as one product.
How to cite
ciltacabtagene autoleucel (AXP000018.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000018.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.